Extended Data Table 2 Overall survival by KRAS mutant allele dosage

From: Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

  1. OS by KRAS mutant allele dosage among patients with KRASMUT tumors evaluable for KRAS allele-specific copy number considered for survival analysis (Methods, n = 865). Multivariable Cox proportional hazards model of OS, stratified by stage at diagnosis and within each stage. Displayed P values are nominal two-sided P values associated with the observed hazard ratios from the multivariable regression models. Bold numbers indicate P values <0.05.
Back to article page